Novavax, Inc. reported a net income of $518.6 million on total revenue of $666.7 million for the three months ended March 31, 2025. This represents a substantial increase compared to a net loss of $147.6 million and total revenue of $93.9 million in the same period last year. The significant revenue growth was primarily due to the termination of advance purchase agreements (APAs) with Canada and New Zealand, and initial revenue recognition from the Sanofi Collaboration and License Agreement.

Novavax reported fourth-quarter revenue of $88 million and a net loss of $81 million. The company is focusing on leveraging its technology platform through partnerships and pipeline expansion, including the transition of its COVID-19 vaccine commercialization to Sanofi and advancing its COVID-19-Influenza Combination vaccine candidate.

Novavax reported total revenue of $85 million for Q3 2024, with product sales contributing $38 million and licensing, royalties, and other revenue at $46 million. The company ended the quarter with $1 billion in cash and receivables and is advancing its R&D strategy beyond COVID-19 and influenza.

Novavax reported second quarter revenue of $415 million, driven by a $391 million upfront payment from Sanofi. The company is progressing with its Sanofi partnership and plans to initiate Phase 3 trials for its COVID-19-Influenza Combination and stand-alone influenza vaccines in Q4 2024.

Novavax announced its Q1 2024 financial results, highlighting a co-exclusive licensing agreement with Sanofi and progress on its COVID-19 vaccine and CIC program.

Novavax reported Q4 2023 revenue of $291 million and a net loss of $178 million. The company is focused on reducing spending, managing cash flow, and advancing its COVID-19-Influenza Combination vaccine candidate.

Novavax reported Q3 2023 revenue of $187 million, compared to $735 million in the same period in 2022. The company is initiating an additional cost reduction program, targeting over $300 million in 2024.

Novavax reported a total revenue of $424 million and a net income of $58 million for the second quarter of 2023. The company has reduced its current liabilities and is progressing with its updated XBB COVID vaccine.

Novavax reported Q1 2023 revenue of $81 million, a significant decrease from $704 million in Q1 2022, reflecting a shift to seasonal demand for COVID vaccines. The company announced a global restructuring and cost reduction initiative, aiming for a 40% to 50% reduction in R&D and SG&A expenses by 2024 compared to 2022. Despite a net loss of $294 million, Novavax is on track to deliver an updated COVID vaccine for the Fall season and announced positive Phase 2 topline results for its COVID-Influenza Combination, standalone influenza, and high dose COVID vaccine candidates.

Novavax reported its Q4 and full year 2022 financial results, highlighting near-term priorities including delivering a competitive product for the 2023 fall vaccination season, reducing the rate of spend and managing cash flow, and leveraging the technology platform to drive additional value.

Novavax reported its Q3 2022 financial results, highlighting the expansion of their COVID-19 vaccine's label, achievement of policy recommendations globally, and expansion of clinical evidence supporting their vaccine technology.

Novavax reported its Q2 2022 financial results, highlighting the delivery of its vaccine to the U.S. market and global distribution with over 23 million doses delivered since the start of Q3.

Novavax reported a successful launch of its protein-based COVID-19 vaccine worldwide, achieving its first profitable quarter with $704 million in revenue.

Novavax's Q4 2021 revenue was $222 million, and the net loss was $846 million. The company had $1.5 billion in cash, cash equivalents, marketable securities, and restricted cash as of December 31, 2021. Novavax expects to achieve full year 2022 total revenue of between $4 billion and $5 billion.

Novavax reported revenue of $178.8 million and a net loss of $322.4 million, or $4.31 per share, for the third quarter of 2021.

Novavax reported a net loss of $352 million for the second quarter of 2021, compared to a net loss of $18 million for the same period in 2020. Revenue increased to $298 million, driven by increased development activities related to NVX-CoV2373. The company had $2.1 billion in cash, cash equivalents and restricted cash as of June 30, 2021.

Novavax reported a net loss of $223 million, or $3.05 per share, for the first quarter of 2021. Revenue was $447 million, a significant increase compared to the same period in 2020, driven by increased development activities relating to NVX-CoV2373.

Novavax reported a net loss of $177.6 million, or $2.70 per share, for the fourth quarter of 2020. Novavax revenue in the fourth quarter of 2020 was $279.7 million.

Novavax reported a net loss of $197.3 million for Q3 2020, compared to a net loss of $18.0 million for Q3 2019. Revenue increased significantly to $157.0 million, driven by increased development activities related to NVX-CoV2373. The company is progressing with multiple clinical trials for its COVID-19 vaccine candidate and expects initial efficacy data potentially by early first quarter 2021.

Novavax reported a net loss of $17.5 million, or $0.30 per share, for the second quarter of 2020, compared to a net loss of $39.6 million, or $1.69 per share, for the second quarter of 2019. Revenue in the second quarter of 2020 was $35.5 million, compared to $3.4 million in the same period in 2019. The increase was due to increased development activities relating to NVX-CoV2373 under the CEPI agreement.

Novavax reported a net loss of $25.9 million, or $0.58 per share, for the first quarter of 2020. Revenue was $3.4 million, a 15% decrease compared to the same period in 2019. The company is focusing on scaling up manufacturing and delivering clinical data for NVX-CoV2373, while preparing the BLA filing for NanoFlu.

Novavax reported a net loss of $31.8 million for Q4 2019, compared to a net loss of $49.3 million for Q4 2018. Revenue increased by 44% to $8.8 million, driven by the recovery of additional costs under the HHS BARDA contract. The company is progressing with its NanoFlu, COVID-19, and ResVax programs.